Charlene D. Fell

2.5k total citations
38 papers, 1.2k citations indexed

About

Charlene D. Fell is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Charlene D. Fell has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 13 papers in Physiology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Charlene D. Fell's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (30 papers), Sarcoidosis and Beryllium Toxicity Research (12 papers) and Pulmonary Hypertension Research and Treatments (7 papers). Charlene D. Fell is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (30 papers), Sarcoidosis and Beryllium Toxicity Research (12 papers) and Pulmonary Hypertension Research and Treatments (7 papers). Charlene D. Fell collaborates with scholars based in Canada, United States and Saudi Arabia. Charlene D. Fell's co-authors include Martin Kolb, Kevin R. Flaherty, Shikha Mittoo, Kerri A. Johannson, Christopher J. Ryerson, Ella A. Kazerooni, Barry H. Gross, William D. Travis, Fernando J. Martínez and Susan Murray and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, CHEST Journal and European Respiratory Journal.

In The Last Decade

Charlene D. Fell

38 papers receiving 1.2k citations

Peers

Countries citing papers authored by Charlene D. Fell

Since Specialization

Citations

This map shows the geographic impact of Charlene D. Fell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlene D. Fell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlene D. Fell more than expected).

Fields of papers citing papers by Charlene D. Fell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlene D. Fell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlene D. Fell. The network helps show where Charlene D. Fell may publish in the future.

Co-authorship network of co-authors of Charlene D. Fell

This figure shows the co-authorship network connecting the top 25 collaborators of Charlene D. Fell. A scholar is included among the top collaborators of Charlene D. Fell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlene D. Fell. Charlene D. Fell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient and Physician Assessments of Clinical Status 2023 ·PubMed ·(unknown), (unknown), (unknown), Charlene D. Fell, Kerri A. Johannson	3
2	Treatment of rheumatoid arthritis-associated interstitial lung disease in a multi-center registry cohort 2023 ·Journal of Thoracic Disease ·Veronica Marcoux, (unknown), Prosanta Mondal, Deborah Assayag, Jolene H. Fisher, Shane Shapera, Julie Morisset, H. Manganas, Charlene D. Fell, Nathan Hambly, Gerard Cox, Martin Kolb, Andrea S. Gershon, Teresa To, Mohsen Sadatsafavi, Nasreen Khalil, Alyson W. Wong, (unknown), Christopher J. Ryerson, Kerri A. Johannson	6
3	Perceptions of Genetic Testing: A Mixed-Methods Study of Patients with Pulmonary Fibrosis and Their First-Degree Relatives 2022 ·Annals of the American Thoracic Society ·(unknown), N. Avitzur, Julie Morisset, Charlene D. Fell, Kerri A. Johannson	3
4	Treatment Initiation in Patients with Interstitial Lung Disease in Canada 2021 ·Annals of the American Thoracic Society ·Deborah Assayag, (unknown), Kerri A. Johannson, Charlene D. Fell, Martin Kolb, Gerard Cox, Nathan Hambly, H. Manganas, Julie Morisset, Jolene H. Fisher, Shane Shapera, Andrea S. Gershon, Teresa To, Mohsen Sadatsafavi, Pearce Wilcox, Andrew J. Halayko, Nasreen Khalil, Christopher J. Ryerson	7
5	Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study 2021 ·Respiratory Medicine ·(unknown), Shane Shapera, Christopher J. Ryerson, Deborah Assayag, Kerri A. Johannson, Charlene D. Fell, Julie Morisset, H. Manganas, Martin Kolb, Nathan Hambly, Gerard Cox, Nasreen Khalil, Veronica Marcoux, Pearce Wilcox, Teresa To, Mohsen Sadatsafavi, Andrew J. Halayko, Andrea S. Gershon, (unknown), Jolene H. Fisher	6
6	Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement 2020 ·Canadian Journal of Respiratory Critical Care and Sleep Medicine ·Jolene H. Fisher, Kerri A. Johannson, Deborah Assayag, Julie Morisset, (unknown), H. Manganas, Shane Shapera, Charlene D. Fell, Christopher J. Ryerson, Martin Kolb	10
7	Costs of Workplace Productivity Loss in Patients with Connective Tissue Disease–associated Interstitial Lung Disease 2020 ·Annals of the American Thoracic Society ·(unknown), Mohsen Sadatsafavi, Jolene H. Fisher, Julie Morisset, Kerri A. Johannson, Charlene D. Fell, Martin Kolb, H. Manganas, (unknown), Andrea S. Gershon, Andrew J. Halayko, Nathan Hambly, Nasreen Khalil, Shane Shapera, Teresa To, Pearce Wilcox, Sabina A. Guler, Christopher J. Ryerson	5
8	Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease 2020 ·Thorax ·(unknown), (unknown), Alyson W. Wong, (unknown), Deborah Assayag, Kerri A. Johannson, Julie Morisset, Charlene D. Fell, Jolene H. Fisher, H. Manganas, Shane Shapera, Gerard Cox, Andrea S. Gershon, Nathan Hambly, Nasreen Khalil, Teresa To, Pearce Wilcox, Andrew J. Halayko, Martin Kolb, Christopher J. Ryerson	38
9	Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis 2019 ·BMC Pulmonary Medicine ·Jolene H. Fisher, Martin Kolb, (unknown), (unknown), Kerri A. Johannson, Shane Shapera, Pearce Wilcox, Teresa To, Mohsen Sadatsafavi, H. Manganas, Nasreen Khalil, Nathan Hambly, Andrew J. Halayko, Andrea S. Gershon, Charlene D. Fell, Gerard Cox, Christopher J. Ryerson	53
10	Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease 2019 ·CHEST Journal ·(unknown), Mohsen Sadatsafavi, Jolene H. Fisher, Julie Morisset, Kerri A. Johannson, Charlene D. Fell, Martin Kolb, H. Manganas, Gerard Cox, Andrea S. Gershon, Andrew J. Halayko, Nathan Hambly, Nasreen Khalil, Shane Shapera, Teresa To, Pearce Wilcox, Sabina A. Guler, Christopher J. Ryerson	15
11	Autoantibody status is not associated with change in lung function or survival in patients with idiopathic pulmonary fibrosis 2019 ·Respiratory Medicine ·G.C. Goobie, (unknown), Marvin J. Fritzler, Kerri A. Johannson, Charlene D. Fell	4
12	Supplemental Oxygen in Interstitial Lung Disease: An Art in Need of Science 2017 ·Annals of the American Thoracic Society ·Kerri A. Johannson, Sachin R. Pendharkar, (unknown), Charlene D. Fell, Jordan A. Guenette, Meena Kalluri, Martin Kolb, Christopher J. Ryerson	33
13	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry 2016 ·Canadian Respiratory Journal ·Christopher J. Ryerson, (unknown), Charlene D. Fell, H. Manganas, Shane Shapera, Shikha Mittoo, Mohsen Sadatsafavi, Teresa To, Andrea S. Gershon, Jolene H. Fisher, Kerri A. Johannson, Nathan Hambly, Nasreen Khalil, Theodore K. Marras, Julie Morisset, Pearce Wilcox, Andrew J. Halayko, (unknown), Martin Kolb	34
14	Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada 2016 ·European Respiratory Journal ·Robert Hopkins, Natasha Burke, Charlene D. Fell, Geneviève Dion, Martin Kolb	121
15	Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis 2016 ·CHEST Journal ·Julie Morisset, Kerri A. Johannson, Eric Vittinghoff, Carlos Aravena, Brett M. Elicker, Kirk D. Jones, Charlene D. Fell, H. Manganas, Bruno‐Pierre Dubé, Paul J. Wolters, Harold R. Collard, Christopher J. Ryerson, Brett Ley	167
16	Idiopathic Pulmonary Fibrosis: Phenotypes and Comorbidities 2012 ·Clinics in Chest Medicine ·Charlene D. Fell	36
17	Clinical Predictors of a Diagnosis of Idiopathic Pulmonary Fibrosis 2010 ·American Journal of Respiratory and Critical Care Medicine ·Charlene D. Fell, Fernando J. Martínez, Lyrica X. Liu, Susan Murray, MeiLan K. Han, Ella A. Kazerooni, Barry H. Gross, Jeffrey L. Myers, William D. Travis, Thomas V. Colby, Galen B. Toews, Kevin R. Flaherty	181
18	The Prognostic Value of Cardiopulmonary Exercise Testing in Idiopathic Pulmonary Fibrosis 2008 ·American Journal of Respiratory and Critical Care Medicine ·Charlene D. Fell, (unknown), (unknown), Ella A. Kazerooni, Barry H. Gross, William D. Travis, Thomas V. Colby, Susan Murray, Galen B. Toews, Fernando J. Martínez, Kevin R. Flaherty	83
19	Sex differences in physiological progression of idiopathic pulmonary fibrosis 2008 ·European Respiratory Journal ·MeiLan K. Han, Susan Murray, Charlene D. Fell, Kevin R. Flaherty, Galen B. Toews, J. D. Myers, Thomas V. Colby, William D. Travis, Ella A. Kazerooni, Barry H. Gross, Fernando J. Martínez	78
20	Glucose-dependent insulinotropic polypeptide stimulated insulin release from a tumor-derived β-cell line (βTC3) 1993 ·Canadian Journal of Physiology and Pharmacology ·(unknown), C. Bruce Verchere, Charlene D. Fell, Zhong‐Xian Huang, John C. Brown, Raymond A. Pederson	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact